Integrum AB (publ) (INTEG_B) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's webcast with Integrum, where the CEO Martin Hylsten and CFO Louise Wolin will present the report for the last quarter. After the presentation, there will be a Q&A. If you have any questions for the company, you can send them in the form to the right. And with that said, I hand over the floor to you. Hello, good morning, thank you for that. Welcome to Integrum's Q4 report. For those who are new to Integrum, we are a Swedish medical technology company with roots in research as the basis for our integration. Our focus is to develop commercial bone-linked implantation systems for amputated prostheses directly connected to the skeleton, instead of via a traditional sleeve. Our main product, OPERA Implant System, is the only FDA-recognized implantation system for amputations in the US. By combining clinical research, innovation and long experience in the area, we are working to improve the function, mobility and quality of life for amputated patients around the world. Before we go into detail, I would like to take a step back and summarize what we have achieved over the past year. Året vi nu stänger har präglat av förändring. Vi har stärkt ledningen, förenklat organisationen och reducerat vår operativa kostnadsbas med cirka 20%. Samtidigt har vi investerat i den kommersiella infrastrukturen som krävs för att stödja framtida tillväxt. Vi inkluderar att stärka vårt nätverk av Centers of Excellence, lansera vår nya digitala plattform och öka vår kommersiella närvaro på viktiga marknader som USA, Ukraina och DASH-regionen. The most important thing is now that we begin to see concrete results of these efforts. During the fourth quarter, we achieved the highest number of SZ operations in the company's history, as well as we saw an increased patient i...